MPI DMSA KIDNEY REAGENT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MPI DMSA KIDNEY REAGENT is a diagnostic radiopharmaceutical injection approved in 1982 for renal imaging. It is a technetium-99m labeled agent used to assess kidney function and detect renal abnormalities. The product works by concentrating in renal tissue, allowing visualization via nuclear imaging.
LOE Approaching
As a mature diagnostic product approaching end-of-life, the brand team is likely small and focused on retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MPI DMSA offers limited career growth opportunity given its mature, diagnostic status and approaching loss of exclusivity. Roles available are primarily focused on compliance, market maintenance, and operational efficiency rather than innovation or expansion.
Regulatory AffairsProduct Manager
Worked on MPI DMSA KIDNEY REAGENT at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.